Xintela (XINT) Q4 2025 earnings summary

Executive summary

• Clinical studies with XSTEM for knee osteoarthritis and difficult-to-heal leg ulcers have been completed, showing strong safety and efficacy results, including disease-modifying potential in osteoarthritis patients.

• Targinta, the oncology subsidiary, entered a collaboration with Memorial Sloan Kettering Cancer Center for clinical development of integrin a10β1-targeted antibodies for aggressive sarcoma.

• GMP operations continue to generate revenue through collaborations and are positioned for self-sufficiency.

• Rights issue and loan financing raised approximately SEK 62 million to support ongoing operations and development.

Financial highlights

• Q4 2025 income was TSEK 415, down from TSEK 1,090 in Q4 2024; full-year income was TSEK 2,282, down from TSEK 4,215.

• Q4 2025 loss before tax was TSEK 17,343 (Q4 2024: loss of TSEK 11,712); full-year loss before tax was TSEK 50,158 (2024: loss of TSEK 41,534).

• Loss per share for Q4 and full year remained at SEK 0.02 and SEK 0.07, respectively.

• Cash and cash equivalents at year-end were TSEK 23,208, up from TSEK 16,680 the previous year.

Outlook and guidance

• Next clinical study with XSTEM in osteoarthritis patients is being prepared, with ongoing discussions for investigator-initiated studies in Europe.

• Results from the leg ulcer study are expected by the end of May, with plans for a phase II study in collaboration with the Burn Center in Linköping.

• Business development efforts are focused on securing partnerships and licensing deals for XSTEM and Targinta's oncology assets.